The aim of this study was to conclusively determine the enzyme responsible for the hydrolysis of oxybutynin in human liver. Hydrolysis in human liver microsomes (HLMs) and cytosol (HLC) followed Michaelis-Menten kinetics with similar K m values. In recombinant human carboxylesterase (CES)-expressing microsomes, CES1 was much more efficient than CES2 and yielded a K m value more comparable to that found in HLMs or HLC than did CES2. A correlation analysis using a set of individual HLMs in which both CESs acted independently showed that the hydrolysis rate of oxybutynin correlated significantly with a CES1 marker reaction, clopidogrel hydrolysis, but not with a CES2 marker reaction, CPT-11 hydrolysis. Chemical inhibition studies using bis-(p-nitrophenyl) phosphate, clopidogrel, nordihydroguaiaretic acid, procainamide, physostigmine, and loperamide revealed that the effects of these compounds in HLMs, HLC, and recombinant CES1-expressing microsomes were similar, while those in CES2-expressing microsomes were clearly different. These results strongly suggest that CES1, rather than CES2, is the principal enzyme responsible for the hydrolysis of oxybutynin in human liver.
Introduction
Oxybutynin hydrochloride is an antimuscarinic agent administered for overactive bladder (Appell et al., 2003; Guay, 2003) , and is primarily metabolized in humans via cytochrome P450 3A4, which yields a dealkylated, pharmacologically active form, N-desethyloxybutynin (Mizushima et al., 2007) . It is also hydrolyzed to a pharmacologically inactive metabolite, 2-cyclohexyl-2-phenylglycolic acid (CPGA) (Abramov and Sand, 2004) (Fig. 1) .
Carboxylesterases (CESs, EC 3.1.1.1) belong to the esterase superfamily involved in the hydrolysis of ester-bearing molecules like oxybutynin (Hosokawa et al., 1995; Hosokawa et al., 2007; Hosokawa, 2008) . Two CES isozymes, CES1 and CES2, are expressed in both the microsomal and cytosolic fractions of human liver (Imai, 2006; Ross and Crow, 2007) , and each has been implicated as the oxybutynin-hydrolyzing enzyme in separate studies. Takai et al. investigated the hydrolytic activity of purified CES proteins on various drugs (Takai et al., 1997) and demonstrated that oxybutynin was hydrolyzed by CES2 (pI 4.5) with K m and V max values of 1.1 mM and 0.36 µmol/min/mg, respectively. Meanwhile, hydrolysis by CES1 (pI 5.3) was below the detection limit (1.0 nmol/min/mg). In contrast, Takahashi et al. investigated the hydrolysis kinetics of oxybutynin in human liver microsomes (HLMs) and cytosol (HLC), and reported K m values between 75 and 120 µM (Takahashi et al., 2008) . They performed a correlation analysis using imidapril as a marker substrate for CES1 activity, and results showed a significant correlation between the formation of imidaprilat and CPGA, indicating that CES1 likely hydrolyzes oxybutynin as well as imidapril. They also reported preliminary data suggesting that the formation of CPGA was inhibited by bis-(p-nitrophenyl) phosphate This article has not been copyedited and formatted. The final version may differ from this version. 
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(BNPP), a well-known CES inhibitor (Heymann and Krisch, 1967; Eng et al., 2010) , but not by loperamide, a CES2 inhibitor (Rivory et al., 1996; Quinney et al., 2005) , although no concrete data regarding the potency of inhibition was given.
Although the hydrolytic potential of CES proteins can be examined using purified protein assays, K m values should be compared with those in HLMs and HLC to assess involvement of CESs in human liver tissue fractions. Additionally, when using a correlation analysis, one cannot define the contribution of each isozyme unless it can be shown that their activities are independent from each other. To resolve this controversy, and identify the oxybutynin-hydrolyzing enzyme in human liver, we performed systematic in vitro experiments. First, we investigated kinetics for oxybutynin hydrolysis in HLMs, HLC, and recombinant human CES-expressing microsomes. Then, adopting clopidogrel and irinotecan (CPT-11) as marker substrates for CES1 and CES2 respectively, we conducted a correlation analysis using a set of 16 individual HLMs. Finally, chemical inhibition studies in human liver tissue fractions and recombinant CESs were conducted using BNPP and several other potential CES inhibitors (clopidogrel, nordihydroguaiaretic acid (NDGA), procainamide, physostigmine (eserine) and loperamide) (Schegg and Welch, 1984; Rivory et al., 1996; Quinney et al., 2005; Shi et al., 2006; Takahashi et al., 2009 
Materials and Methods

Chemicals and Reagents
Oxybutynin hydrochloride, clopidogrel carboxylic acid, clopidogrel-d4 carboxylic acid (internal standard for clopidogrel carboxylic acid quantitation), CPT-11 hydrochloride trihydrate, and SN-38 were purchased from Toronto Research Chemicals (Toronto, ON, Canada (Wang et al., 2011) . All other chemicals and reagents used were commercially available, and guaranteed of purity.
Hydrolysis Assays
The assays were performed according to Tang et al. (Tang et al., 2006) . Briefly, hydrolysis of oxybutynin was carried out at 37 °C in 100 μ L of 0.05 mol/L Tris-HCl buffer (pH 7.6). After pre-incubation at 37 °C for 5 min, the reaction was initiated by adding an oxybutynin solution prepared using the same buffer. In chemical inhibition studies, the inhibitor solution prepared using the same buffer was added just prior to the pre-incubation step. Some inhibitor solutions were prepared by dissolving with 7 DMSO before diluting with the buffer solution. In these cases, the final DMSO concentration in the reaction mixture was 0.2%, which was confirmed to have no effect on the hydrolysis of oxybutynin. The reaction was terminated by adding 150 μ L acetonitrile (ACN) with 1% (v/v) formic acid containing internal standard (IS) for subsequent HPLC analysis. After centrifugation at 1870 × g for 10 min at 4 °C, the supernatant was mixed with the HPLC mobile phase. All assays were performed in duplicate.
Bioanalysis
The formation of hydrolysates, CPGA, clopidogrel carboxylate and SN-38 was determined using HPLC tandem mass spectrometry. The system comprised a Prominence HPLC system (Shimadzu, Kyoto, Japan) with a Synergi Fusion-RP 100A 50 × 2.00 mm, 2.5-micron, column (Phenomenex, Torrance, CA, USA) and a The intrinsic clearance (CL int ) was calculated by dividing V max by K m .
Correlation Analysis
The hydrolysis rates of clopidogrel ( This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Kinetics Studies
The formation of CPGA in HLMs and HLC showed single component Michaelis-Menten kinetics as indicated by the Eadie-Hofstee plots (Fig. 2, A and B) .
Kinetics parameters are summarized in 
Correlation Analysis
While clopidogrel is a CES1-specific substrate (Tang et al., 2006) , CPT-11 is a dual CES substrate whose hydrolysis is catalyzed by both CES1 and CES2 at high substrate concentrations but is hydrolyzed predominantly by CES2 at low concentrations (Slatter et al., 1997) . Therefore, hydrolysis rates of CPT-11 at different concentrations were measured to ensure that we could assess CES1 and CES2 activity independently. The (Takahashi et al., 2008) . Although the precise reason for this discrepancy remains unknown, it might be due to differences in reaction conditions, as the reaction mixture prepared by Takahashi (Guay, 2003) . The V max and CL int values in the present study were similar in HLMs and HLC, which might be surprising given that expression of CESs in HLMs has been reported to be higher than in HLC . However, values in the present study might be possible because V max values were within ranges reported previously (Takahashi et al., 2008 In HLMs, protein expression of CES1 has been reported to be markedly higher than of CES2 (1070 and 23.0 pmol/mg microsomal protein, respectively) (Godin et al., 2007; Ross and Crow, 2007) . Taken together, these results suggest the contribution of CES1
to the hydrolysis of oxybutynin in HLMs to be much higher than that of CES2.
To test this hypothesis, we performed a correlation analysis using a set of 16 individual HLMs. In some previous studies, statistically significant correlations were observed between the CES marker activity and the activity of the test substance (Yamaori et al., 2006; Takahashi et al., 2008; Hagihara et al., 2009) . However, to conclude whether CES1 or CES2 is involved in HLMs, the independence of the different CES isozyme activities must be established in advance. Therefore, we investigated the independence of CES1 and CES2 activities using clopidogrel and CPT-11 as respective marker substrates. Clopidogrel is exclusively hydrolyzed to its carboxylate by CES1 (Hagihara et al., 2009; Farid et al., 2010) , with a K m of 58
HLMs (Tang et al., 2006) . CPT-11 is hydrolyzed to SN-38 (Satoh et al., 1994; Haaz et al., 1997) , and catalyzed predominantly by CES2 at low concentrations (under 5 μ M)
in HLMs (Slatter et al., 1997; Xu et al., 2002; Takahashi et al., 2009 ).
In the present study, regression analysis showed an insignificant correlation between the hydrolysis rates of clopidogrel at 5 μ M and CPT-11 at 1 μ M (Fig. 3A) ,
indicating that use of a correlation analysis to differentiate between CES1 and CES2 activity is feasible. Further, the significant correlation observed between the hydrolysis rates of clopidogrel and CPT-11 at 100 CPT-11 concentration when used as a CES2 marker substrate (Fig. 3B ). In the same individual HLMs, the hydrolysis of oxybutynin correlated well with the hydrolysis rate of clopidogrel but poorly with that of CPT-11 at 1 μ M (Fig. 4) , clearly suggesting that the major isozyme responsible for oxybutynin hydrolysis in HLMs is CES1, not CES2.
Finally, chemical inhibition studies were conducted in HLMs, HLC, and recombinant CESs using 6 compounds (BNPP, clopidogrel, NDGA, procainamide, eserine and loperamide) (Fig. 5) . BNPP is a well-known irreversible, non-selective CES inhibitor (Heymann and Krisch, 1967; Eng et al., 2010) . This article has not been copyedited and formatted. The final version may differ from this version. 
